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Objective
To define a definition of remission in juvenile dermato-
myositis (JDM) that is stringent but achievable and
could be applied uniformly as an outcome measure in
clinical trials.
Methods
275 patients in active phase of JDM <18 years, median
disease duration 7.7 months, were evaluated at baseline
and 24 months. Out of 275 patients, all patients (39/
275) who were off treatment at 24 months were defined
as being in clinical remission and were included as the
“gold standard” group. A random sample of patients
(n=78) who were in an active phase of JDM at baseline
and on medications at 24 months, were selected as the
“comparison group”. Literature was reviewed for defini-
tions of remission and in addition other definitions were
tested which included PRINTO core set variables, mus-
cle enzymes, and other JDM activity measures. Accuracy
measurements were calculated: sensitivity, specificity,
Youden index, Cohen’s kappa (≥0.8 almost perfect).
Results
Four best single variables with kappa≥0.8 were Manual
Muscle Testing (MMT)≥78 (sensitivity: 0.92, specificity
0.97, kappa 0.9), followed by Physician Global Assess-
ment of Muscle Activity (PhyMAVAS) and Physician
Global Visual Analogue Scale (PhyGloVAS)≤0.2 and
Childhood Myositis Assessment Scale (CMAS)≥48. The
most accurate combination of variables with kappa≥0.8
included 4 variables with 3 out of 4 required to be pre-
sent: creatine phosphokinase ≤150, CMAS≥48,
MMT≥78, PhyGloVAS≤0.2 (sensitivity 0.94, specificity
1.00, kappa 0.96).
Conclusion
The combination definition performed the best overall
in defining remission in JDM and could be used for the
evaluation of global response to therapy in future clini-
cal trials.
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